Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Employment/Membership › Details

Strike Pharma–Winge M: management, 202104– CEO before Cartana + Pyrosequencing + Olink + Halo Genomics + Doxa + Proxeon


Period Period 2021-04-28
Organisations Organisation Strike Pharma AB
  Organisation 2 Cartana AB
  Group 10x Genomics (Group)
Products Product Immune Gas Pedal technology (IMMGAP)
  Product 2 BIOTECH
Person Person Winge, Mårten (Strike Pharma 202104– CEO before Cartana + Pyrosequencing + Olink + Halo genomics + Doxa + Proxeon)

Strike Pharma AB. (4/28/21). "Press Release: Personalised Immunotherapy Start-up Strike Pharma Appoints Industry Veteran Mårten Winge as New CEO". Uppsala.

STRIKE Pharma, (“STRIKE”) a Swedish start-up focused on personalized immunotherapy today announced the appointment of Pyrosequencing and Olink veteran Mårten Winge as CEO. Founded in 2020 out of Uppsala University, STRIKE’s vision is to provide an affordable and scalable personalized immunotherapy to treat solid tumors by commercializing the proprietary Immune Gas Pedal technology (IMMGAP).

IMMGAP is based on research by Associate professor Sara Mangsbo at Uppsala University and has been co-developed with the SciLifeLab’s Drug Discovery and Development Platform. While the primarily focus is on cancer, the technology has the potential to become a generic delivery method for any type of disease.

Winge has a Master of Science in Molecular Biology from Karolinska Institute, and over the past twenty years he has held executive management and board positions at Pyrosequencing, Olink, Halo Genomics and Proxeon. Most recently he was CEO of Cartana AB, which was acquired by 10x Genomics. He is currently on the board of Countagen and Inhalation Sciences, acts as an advisor to Inossia, and is a business coach for Uppsala Innovation Center.

“IMMGAP effectively utilizes our own bodies as factories to produce immune cells that can later be used to eliminate tumors. Our ambition is to transform how individualized cancer therapies are being developed,” says Mangsbo. “Mårten has extensive experience of international marketing and business development, and commercializing new technology in life science, primarily in start-up and early growth companies. His business skills and experience will enable STRIKE Pharma to move into the next phase of business and corporate development. I am pleased to welcome him onboard.”

“I am delighted to have the opportunity to work with this extraordinarily talented and knowledgeable team of individuals. I believe that STRIKE Pharma is remarkably well positioned to have a major impact on the rapidly developing field of precision medicine and future individualized treatments,” commented Winge.

With Mårten as CEO, Wing Cheng, previous CEO, will focus on quality assurance, regulatory compliance and market access to enable IMMGAP’s successful transition into clinical use. The team has also been strengthened by the scientific advisor Associate professor Johan Botling, who will provide expert advice on the clinical entry road ahead based on his experience implementing molecular diagnostics for tailored cancer therapies and immune oncology for the last 15 years.

For further information, please contact:

Sara Mangsbo,
Co-founder and inventor
Tel: +46 (0) 73 933 92 05

Mårten Winge,
Tel: +46 (0)70657 5927

To meet the global demand for improved cancer therapeutics and future vaccines, STRIKE Pharma was established in 2020. Its proprietary IMMGAP-technology is a platform for protein-based drugs comprising a high-affinity delivery system that improves the half-life and the delivery of any peptide-based drug.

STRIKE Pharma was founded by Sara Mangsbo together with Wing Cheng, Johan Rockberg, Pierre Dönnes and Michael Akhras, forming a team of wide-ranging expertise in immunotherapy with specialists in AI, genomics, epitope prediction, scalability and production of biologics.

More information;

Record changed: 2021-05-15


Picture [iito] Plain Stupid Simple 650x80px

More documents for Strike Pharma AB

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Demy-Colton BioFuture 2021 NYC A October 650x80px

» top